Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Mallinckrodt
Express Scripts
Harvard Business School
Merck

Last Updated: September 25, 2022

DORYX MPC Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Doryx Mpc, and when can generic versions of Doryx Mpc launch?

Doryx Mpc is a drug marketed by Mayne Pharma and is included in one NDA. There are five patents protecting this drug and five Paragraph IV challenges.

This drug has two patent family members in two countries.

The generic ingredient in DORYX MPC is doxycycline hyclate. There are twenty-eight drug master file entries for this compound. Seventy suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Doryx Mpc

A generic version of DORYX MPC was approved as doxycycline hyclate by CARIBE HOLDINGS on November 8th, 1982.

  Try it Free

Paragraph IV (Patent) Challenges for DORYX MPC
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
DORYX MPC Delayed-release Tablets doxycycline hyclate 60 mg and 120 mg 050795 1 2017-09-28
DORYX MPC Delayed-release Tablets doxycycline hyclate 50 mg 050795 1 2015-11-05
DORYX MPC Delayed-release Tablets doxycycline hyclate 80 mg 050795 1 2015-07-01
DORYX MPC Delayed-release Tablets doxycycline hyclate 200 mg 050795 1 2014-05-19
DORYX MPC Delayed-release Tablets doxycycline hyclate 150 mg 050795 1 2008-12-19

US Patents and Regulatory Information for DORYX MPC

DORYX MPC is protected by five US patents.

Patents protecting DORYX MPC

Modified release coated drug preparation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET

Tabletting process
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Controlled release doxycycline
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET

Controlled release doxycycline
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET

Controlled release doxycycline
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-007 May 20, 2016 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-008 May 20, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-007 May 20, 2016 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-008 May 20, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-007 May 20, 2016 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-007 May 20, 2016 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-008 May 20, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Merck
Boehringer Ingelheim
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.